KPKathryn Elizabeth Post

Kathryn Elizabeth Post

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathryn Elizabeth Post has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Improving adjuvant endocrine therapy initiation among patients with breast cancer: a nurse-led, culturally sensitive pilot study

    by Kathryn E. Post, Laura Dunderdale, Shibani Datta, Leticia Varella, Nora Horick, Lara Traeger, Joseph A. Greer, Beverly Moy, Jennifer S. Temel, Jamie M. Jacobs

    Purpose Up to 30% of patients with hormone receptor-positive (HR +) breast cancer do not start adjuvant endocrine therapy (AET) as prescribed. AET non-initiation is associated with increased recurrence and decreased survival. We conducted a single-arm, open-pilot study to assess the feasibility and acceptability of a nurse-led, culturally sensitive intervention (‘INITIATE’) to optimize AET initiation. Methods From 9/2022 to 8/2024, we recruited 35 patients with stage I-IIIB, HR + breast cancer who delayed or reported hesitancy to start AET. INITIATE included two virtual sessions delivered in English or Spanish with an oncology nurse. Feasibility was defined by enrollment rates (> 50% eligible patients), intervention attendance (≥ 70% of patients attending one of two sessions), and retention (> 70% completing the 3-month questionnaire). At baseline, 1 month, and 3 months post-baseline, patients self-reported sociodemographics, AET initiation, intervention acceptability (Client Satisfaction Questionnaire-3), and other psychosocial outcomes. We conducted semi-structured, qualitative exit interviews to gather additional feedback. We computed descriptive statistics for the quantitative outcomes and conducted a rapid qualitative analysis of the interview data. Results We enrolled 45.5% (35/77) of eligible patients; 82.9% (29/35) attended at least one intervention session, and 77.1% (27/35) completed the 3-month assessment. Most patients (68.6%) were White, and 37.1% identified as a racial or ethnic minority. Qualitatively, patients reported that INITIATE helped them understand the importance of taking AET and improved their coping skills. Ninety-six percent reported high acceptability, and 88.9% started their AET by three months post-baseline. Conclusion INITIATE is mostly feasible and acceptable and demonstrates promise for promoting AET initiation among patients with HR + breast cancer.

  • Development and refinement of a nurse-led, culturally sensitive intervention for adjuvant endocrine therapy initiation among patients with breast cancer

    by Kathryn E. Post, Laura Dunderdale, Shibani Datta, Nichole Gutierrez, Leticia Varella, Nora Horick, Lara Traeger, Joseph A. Greer, Beverly Moy, Jennifer S. Temel, et al.


  • CDK4/6 Inhibitors in Patients with Breast Cancer: A Review of Adverse Event Profiles and Recommendations for Supportive Care Interventions

    by Kathryn E. Post, Mia Holtze, Steven J. Isakoff, Leif W. Ellisen, Jamie M. Jacobs, Seth A. Wander, Joseph A. Greer


  • Depression and Anxiety as Moderators for a Behavioral Treatment for Dyspnea in Advanced Lung Cancer

    by Stephen B. Lo, Mia Holtze, Kathryn E. Post, Ijeoma Julie Eche-Ugwu, Mary E. Cooley, William F. Pirl, Jennifer S. Temel, Joseph A. Greer


  • Not out of the woods: perspectives from patients with triple-negative breast cancer

    by Kathryn E. Post, Seetha Aribindi, Lara Traeger, Daniel Hall, Jamie Jacobs, Jennifer S. Temel, Joseph A. Greer

    Purpose Patients with triple-negative breast cancer (TNBC) are at high risk for breast cancer recurrence and metastatic disease, yet the scholarly literature on the distress and uncertainty of this vulnerable population is limited. This study aimed to characterize the experiences of patients with TNBC and obtain feedback about the development of a supportive care intervention targeted to this population’s psychosocial needs. Methods From 9/2021 to 2/2023, we purposefully recruited 23 patients with stage I–III TNBC who recently completed curative therapy and conducted a parallel mixed qualitative and quantitative study. We conducted in-depth semi-structured interviews regarding the transition from curative therapy to surveillance. Patients also completed self-report measures of fear of cancer recurrence (FCR) (Fear of Cancer Recurrence Inventory Severity) and psychological distress (Hospital Anxiety and Depression Scale; PROMIS Anxiety). Results Patients were, on average, 51 years old (SD = 13.56). Most patients (87.0%) reported elevated FCR (cutoff = 16; M = 18.91; SD = 6.22). Major themes identified in the qualitative interviews included feelings of dissimilarity among other breast cancer survivors, quality of life interference persisting in the surveillance phase, “shifting the focus away from cancer” as a coping strategy, and FCR as a primary concern. Patients also shared preferences for a TNBC-specific supportive care intervention. Conclusion Patients with TNBC experience significant challenges during the transition from curative therapy to surveillance and desire psychosocial support during this critical period. These findings illustrate potential intervention targets for a future supportive care intervention tailored to patients with TNBC.


  • Effects of Adjuvant Endocrine Therapy–Specific Perceptions on Response to a Behavioral Intervention for Adjuvant Endocrine Therapy Adherence in Patients With Breast Cancer

    by Kelcie D. Willis, Emily A. Walsh, Laura E. Dunderdale, Kathryn Post, Nora Horick, Michael H. Antoni, Steven A. Safren, Ann H. Partridge, Jeffrey Peppercorn, Elyse R. Park, et al.

    PURPOSE: Adjuvant endocrine therapy (AET) is a life-saving medication for patients with hormone-sensitive breast cancer, yet many struggle with adherence, warranting behavioral intervention. In our recent trial, participation in a group cognitive behavioral intervention (STRIDE) for symptom management and adherence was associated with improvements in symptom distress, coping, quality of life, and mood. We now explore whether baseline patient- and medication-specific factors—which may be modifiable by clinician-led discussions—moderated the effect of STRIDE on adherence rates. METHODS: From October 2019 to June 2021, 100 patients with early-stage breast cancer reporting AET-related distress were enrolled and randomly assigned to STRIDE or a medication monitoring (MM) control group. All patients stored their AET in electronic pill bottles to track objective adherence. Patients also self-reported their adherence on the Medication Adherence Report Scale-5 and their perceptions of AET on the Cancer Therapy Satisfaction Questionnaire at baseline. We conducted hierarchical linear modeling to test moderators of intervention effects on objective adherence rates. We report the time × group × moderator effects. RESULTS: Among patients reporting greater perceived difficulties with AET adherence at baseline, STRIDE participants had higher adherence rates over time compared with MM ( b = –13.80; SE = 4.56; P < .01). Patients with greater expectations of therapeutic benefit from AET also had improved adherence rates if they were assigned to STRIDE, versus MM ( b = 0.25; SE = 0.10; P = .01). Patients who perceived taking AET as convenient and had been taking their AET for less time had higher adherence rates in STRIDE, versus MM. CONCLUSION: The current study identified patient- and medication-specific factors that may augment AET adherence interventions and may be modifiable through clinician-led discussions, such as perceptions of adherence problems, therapeutic efficacy, and convenience of AET.


  • Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer

    by Joseph A. Greer, Kathryn E. Post, Reena Chabria, Seetha Aribindi, Natalie Brennan, Ijeoma Julie Eche-Ugwu, Barbara Halpenny, Erica Fox, Stephen Lo, Lauren P. Waldman, et al.

    PURPOSE: In patients with lung cancer, dyspnea is one of the most prevalent and disabling symptoms, for which effective treatments are lacking. We examined the efficacy of a nurse-led brief behavioral intervention to improve dyspnea in patients with advanced lung cancer. METHODS: Patients with advanced lung cancer reporting at least moderate breathlessness (n = 247) were enrolled in a randomized trial of a nurse-led two-session intervention (focused on breathing techniques, postural positions, and fan therapy) versus usual care. At baseline and weeks 8 (primary end point), 16, and 24, participants completed measures of dyspnea (Modified Medical Research Council Dyspnea Scale [mMRCDS]; Cancer Dyspnoea Scale [CDS]), quality of life (Functional Assessment of Cancer Therapy-Lung [FACT-L]), psychological symptoms (Hospital Anxiety and Depression Scale), and activity level (Godin-Shephard Leisure Time Physical Activity Questionnaire). To examine intervention effects, we conducted analysis of covariance and longitudinal mixed effects models. RESULTS: The sample (Age mean = 66.15 years; 55.9% female) primarily included patients with advanced non–small cell lung cancer (85.4%). Compared with usual care, the intervention improved the primary outcome of patient-reported dyspnea on the mMRCDS (difference = –0.33 [95% CI, –0.61 to –0.05]) but not the CDS total score at 8 weeks. Intervention patients also reported less dyspnea on the CDS sense of discomfort subscale (difference = –0.59 [95% CI, –1.16 to –0.01]) and better functional well-being per the FACT-L (difference = 1.39 [95% CI, 0.18 to 2.59]) versus the control group. Study groups did not differ in overall quality of life, psychological symptoms, or activity level at 8 weeks or longitudinally over 24 weeks. CONCLUSION: For patients with advanced lung cancer, a scalable behavioral intervention alleviated the intractable symptom of dyspnea. Further research is needed on ways to enhance intervention effects over the long-term and across additional outcomes.


  • Dyspnea-Related Dimensions And Self-Efficacy: Associations With Well-Being in Advanced Lung Cancer

    by Stephen B. Lo, Anna L. Ruprecht, Kathryn E. Post, Ijeoma Julie Eche-Ugwu, Mary E. Cooley, Jennifer S. Temel, Joseph A. Greer


  • Managing Symptom Distress: Key Factors for Patients on Adjuvant Endocrine Therapy for Breast Cancer

    by Kathryn E. Post, Zeba Ahmad, Greta Jankauskaite, Joely Centracchio, Laura Oswald, Nora Horick, Elyse R. Park, Jennifer S. Temel, Joseph A. Greer, Jamie Jacobs


  • Perceptions of prognosis in patients with advanced lung cancer: Associations with patient demographics, quality of life, and depression symptoms.

    by Jacqueline Han, Kathryn Elizabeth Post, Emily R Gallagher-Medeiros, Chardria Trotter, Lauren Heuer, Rachel Plotke, Yael Turk, Simone Rinaldi, Mihir Kamdar, Vicki A. Jackson, et al.

    247 Background: Despite the importance of having a clear understanding of the likely outcome of cancer to inform medical decision-making, about one third of patients with advanced lung cancer report inaccurate perceptions of their prognosis. To identify factors associated with lower and higher prognostic understanding, we examined the relationships among patients’ perceptions of prognosis and their demographic characteristics, quality of life (QOL), and mood symptoms. Methods: We conducted a cross-sectional analysis of baseline data from patients enrolled in two multisite palliative care trials. Eligible participants included adults with advanced non-small cell lung cancer, small cell lung cancer, or mesothelioma diagnosed in the past 12 weeks and an ECOG Performance Status <3 across 23 cancer centers in the US. At baseline, patients self-reported their current health status and understanding of whether their cancer is curable. Patients’ prognostic understanding was categorized into three levels: “high” if patients reported that their illness was terminal and incurable, “medium” if patients reported that their illness was either terminal or incurable, and “low” if patients reported that their illness was neither terminal nor incurable. To assess QOL and depression symptoms, patients completed the Functional Assessment of Cancer Therapy-Lung (FACT-L) and the Patient Health Questionnaire-9 (PHQ-9), respectively. Linear regression models adjusting for patient demographic factors were used to examine the associations among prognostic understanding, QOL, and depression symptoms. Results: The sample included 1430 patients with advanced lung cancer (Mean age = 65.50 years; 52.5% female; 4.0% Asian, 10.6% Black, 81.8% White; 65.9% married). Patient-reported prognostic understanding varied as follows: high (45.1%), medium (32.7%), and low (22.2%). Patients who were older (p =.015), male (p <.001), Black or Asian (p =.015), or married (p =.012) had lower prognostic understanding. Adjusting for demographic factors, patients with higher prognostic understanding reported worse QOL (FACT-L: B = -5.392, SE = 0.71, p <.001) and depression symptoms (PHQ-9: B = 0.99, SE = 0.19, p < 0.001) versus those with lower prognostic understanding. Conclusions: A substantial proportion of patients with newly diagnosed advanced lung cancer have low prognostic understanding. Those with high prognostic understanding report worse QOL and depression symptoms, which may be due to patients relating their poor health status to their prognosis. Furthermore, patient age, gender, race, and relationship status are salient correlates of prognostic understanding. Tailored interventions are needed to improve illness understanding and address the related supportive care needs of patients with advanced lung cancer, especially those at risk for low prognostic understanding.